These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 26587015)

  • 1. Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.
    Lee WS; Kim J
    PPAR Res; 2015; 2015():271983. PubMed ID: 26587015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
    Latruffe N; Vamecq J
    Biochimie; 1997; 79(2-3):81-94. PubMed ID: 9209701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials.
    Arck P; Toth B; Pestka A; Jeschke U
    Biol Reprod; 2010 Aug; 83(2):168-76. PubMed ID: 20427759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview on biological mechanisms of PPARs.
    Kota BP; Huang TH; Roufogalis BD
    Pharmacol Res; 2005 Feb; 51(2):85-94. PubMed ID: 15629253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
    Ivanova EA; Myasoedova VA; Melnichenko AA; Orekhov AN
    Curr Pharm Des; 2017; 23(7):1119-1124. PubMed ID: 27855608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Peroxisome proliferator activated receptors (PPAR) and insulin sensitivity: experimental studies].
    Haluzík MM; Haluzík M
    Cesk Fysiol; 2006; 55(4):163-8. PubMed ID: 17685022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR: a mediator of peroxisome proliferator action.
    Green S
    Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
    Ahsan W
    Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.
    Schoonjans K; Staels B; Auwerx J
    Biochim Biophys Acta; 1996 Jul; 1302(2):93-109. PubMed ID: 8695669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome Proliferated Activated Receptors (PPARs): Opportunities and Challenges for Ocular Therapy.
    Khatol P; Saraf S; Jain A
    Crit Rev Ther Drug Carrier Syst; 2018; 35(1):65-97. PubMed ID: 29611471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.
    Desouza CV; Rentschler L; Fonseca V
    Diabetes Metab Syndr Obes; 2009 Sep; 2():165-72. PubMed ID: 21437130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
    Bocher V; Chinetti G; Fruchart JC; Staels B
    J Soc Biol; 2002; 196(1):47-52. PubMed ID: 12134632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
    Guan Y
    Minerva Urol Nefrol; 2002 Jun; 54(2):65-79. PubMed ID: 12185990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
    Feldman PL; Lambert MH; Henke BR
    Curr Top Med Chem; 2008; 8(9):728-49. PubMed ID: 18537685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PPAR family and its relationship to metabolic syndrome].
    Zhang XY; Chen LH; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.